This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HGT 3010

Shire Pharmaceuticals Group PLC

Drug Names(s): HGT 3010

Description: HGT 3010 is an intrathecally delivered enzyme replacement therapy for patients with Sanfilippo B Syndrome (Mucopolysaccharidosis IIIB). Sanfilippo B occurs when a person is missing or does not produce enough alpha-N-acetylglucosaminidase.

Deal Structure: Abbvie and Shire
In July 2014, AbbVie and Shire announced that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.

In October 2014, AbbVie and Shire have agreed to terminate their proposed merger following the decision by AbbVies Board to withdraw support for the proposed transaction. The Companys decision was based upon its assessment of the September 22, 2014 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions.

HGT 3010 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug